Dapagliflozin in Children: Age Limits and Caregiver Guidance
Farxiga is not FDA-approved under age 12 (or 10 for type 2 diabetes in some guidelines). Learn why, plus DKA risks and when to consult a pediatric specialist.
Age V2 Dapagliflozin
10 source-based articles maintained by the HealthRX.com Editorial Team.
10articles
3topic areas covered
Jan 30, 2025latest review
Age V2 Dapagliflozin library
Showing 10 of 10 clinical reviews.
Farxiga (Dapagliflozin) Caregiver Administration Guide for Adolescents Ages 12 to 17
A guide for caregivers administering Farxiga (dapagliflozin) to adolescents ages 12 to 17 with type 1 or type 2 diabetes, covering dosing, safety monitoring, sick-day rules, and when to call the prescriber.
Farxiga (Dapagliflozin) in Adolescents Ages 12 to 17: Developmental Impact
A guide to how dapagliflozin (Farxiga) affects growth, bone, kidney, metabolic, and pubertal development in adolescents aged 12 to 17, with clinical trial data, dosing guidance, and monitoring protocols.
Farxiga (Dapagliflozin) in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Considerations
A comprehensive clinical review of off-label dapagliflozin use in adolescents ages 12 to 17, covering the evidence base, dosing, safety signals, and how prescribers are applying this SGLT2 inhibitor in pediatric type 2 diabetes and beyond.
Farxiga (Dapagliflozin) in Adults 65 and Older: What the Evidence Actually Shows
A guide to dapagliflozin (Farxiga) use in geriatric patients: efficacy, safety, dosing considerations, and trial data for adults 65 and older with type 2 diabetes, heart failure, or CKD.
Farxiga (Dapagliflozin) in Children Under 12: What Families Need to Know About Transition to Adult Care
A comprehensive clinical guide covering dapagliflozin use in pediatric patients under age 12, current FDA approval status, and how to plan a safe, structured transition to adult endocrine and cardiology care.
Farxiga (Dapagliflozin) in Children Under 12: What the Off-Label Evidence Actually Shows
A clinician-facing review of off-label dapagliflozin use in children under 12, covering the pharmacology, available trial data, dosing considerations, and current guideline positions.
Farxiga Adolescent (12 to 17) Transition to Adult Care: A Complete Clinical Guide
Everything clinicians and patients need to know about transitioning adolescents aged 12 to 17 from pediatric to adult care while continuing dapagliflozin (Farxiga) for type 1 or type 2 diabetes.
Farxiga Geriatric (65+) Caregiver Administration Guidance
Complete caregiver guide to administering Farxiga (dapagliflozin) to adults aged 65 and older: dosing, timing, fall and dehydration risks, renal monitoring, and when to call the prescriber.
Farxiga Geriatric (65+) School and Activity Considerations
A guide to dapagliflozin (Farxiga) use in adults 65 and older, covering physical activity safety, fall risk, hydration, dosing, and practical monitoring strategies for active older adults.